(Figure 7) Compared to the blank control group, this strategy increased the antiviral efficiency from 9.28% to 91.33% and significantly alleviated the hyperinflammatory state of COVID‐19 by adsorbing inflammatory factors such as IL‐6, IL‐1β, and TNF‐α (Wang et al., 2022c). Here, IL1B is linked to COVID-19.